First-line therapy: nivolumab plus ipilimumab vs. nivolumab alone vs. chemotherapy for NSCLC with PD-L1 expression in >/=1% tumor cells; nivolumab plus ipilimumab vs. nivolumab plus chemotherapy vs. chemotherapy for NSCLC with PD-L1 expression in <1% tumor cells. This evidence concerns the gene CD274 and non-small cell lung carcinoma.